Results 61 to 70 of about 2,408 (176)

Poster Sessions

HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source

Publication Only

HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source

ISEV2026 Abstract Book

Journal of Extracellular Vesicles, Volume 15, Issue S1, June 2026.
wiley   +1 more source

ePoster

European Journal of Neurology, Volume 33, Issue S1, June 2026.
wiley   +1 more source

Population Pharmacokinetics and Exposure‐Response Modeling for Evinacumab in Children, Adolescents, and Adults With Homozygous Familial Hypercholesterolemia

CPT: Pharmacometrics & Systems Pharmacology
Evinacumab, an angiopoietin‐like 3 (ANGPTL3) inhibitor, significantly reduces low‐density lipoprotein cholesterol (LDL‐C), independent of low‐density lipoprotein receptor, in patients with homozygous familial hypercholesterolemia (HoFH).
Sébastien Bihorel, Robert Dingman, Jeanne Mendell, Yuhuan Wang, Poulabi Banerjee, Robert Pordy, John D. Davis, A. Thomas DiCioccio, Lutz Harnisch   +8 more
doaj   +1 more source

Low-Density Lipoprotein Apheresis in Patients with Acute Kidney Injury Due to Minimal Change Disease Requiring Acute Renal Replacement Therapy

International Journal of Nephrology and Renovascular Disease, 2020
Kohsuke Terada, Koji Mugishima, Sayuri Kawasaki, Fumiaki Itagaki, Takehisa Yamada, Yukinao Sakai Department of Nephrology, Graduate School of Medicine, Nippon Medical School, Tokyo, JapanCorrespondence: Yukinao SakaiDepartment of Nephrology, Graduate ...
Terada K, Mugishima K, Kawasaki S, Itagaki F, Yamada T, Sakai Y   +5 more
doaj  

Outpatient monthly plasmapheresis with post-PLEX evinacumab in pediatric homozygous familial hypercholesterolemia: a case report on port access and immunoglobulin preservation

Frontiers in Pediatrics
Homozygous familial hypercholesterolemia (HoFH) is a rare genetic disorder characterized by severely elevated low-density lipoprotein (LDL) cholesterol levels, predisposing patients to early cardiovascular disease.
Guido Filler, Kambiz Norozi, Kambiz Norozi   +2 more
doaj   +1 more source

Abstracts of the 18th SCWD Conference, 11‐13 December 2025 in Rome/Italy

JCSM Communications, Volume 9, Issue 1, January/June 2026.
wiley   +1 more source

CLINICAL APPLICATION OF HELP-APHERESIS IN FEMALE PATIENT WITH FAMILIAL HYPERCHOLESTEROLEMIA

Фундаментальная и клиническая медицина, 2018
Cardiovascular diseases caused by atherosclerosis and its complications represent the leading cause of death in developed countries. The main risk factor of atherosclerosis development is dyslipidemia, in particular familial hypercholesterolemia (FH ...
OLGA L. Barbarash, NATALIA V. Fedorova, VASILIY V. Kashtalap, ROMAN A. Kornelyuk, OLESYA E. Astafurova, DMITRIY L. Shukevich, OLGA V. Gruzdeva   +6 more
doaj  

Long-term effectiveness and safety of lomitapide in patients with homozygous familial hypercholesterolemia: an observational case series

Orphanet Journal of Rare Diseases
Background We assessed long-term real-world effectiveness and safety of lomitapide in patients with homozygous familial hypercholesterolemia (HoFH). Methods Retrospective case series of six patients with HoFH treated with lomitapide in an Italian clinic.
Patrizia Suppressa, Chiara Coppola, Veronica Cocco, Sallyann O’Brien   +3 more
doaj   +1 more source